Moderna's MRNA +3.99% Get Free Report short percent of float has risen 13.6% since its last report. The company recently ...

H.C. Wainwright reaffirmed a Buy rating on Cartesian Therapeutics shares, maintaining the $45.00 price target, representing a ...

A new class of lipids developed by Penn Engineers improve the rates at which lipid nanoparticles (LNPs) successfully deliver ...

Ramakrishnan, a distinguished structural biologist and Nobel Laureate in Chemistry (2009), is renowned for his groundbreaking ...

The Kowalinski group at EMBL Grenoble discovered notable differences between the nuclear cap-binding complex in trypanosomes and humans, a critical component in cellular RNA metabolism. Trypanosomes ...

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

Moderna, Inc. (NASDAQ:MRNA) institutional owners may be pleased with recent gains after 65% loss over the past year Given the large stake in the stock by institutions, Moderna's stock price might be ...

A new study from the Kowalinski group at EMBL Grenoble characterized the structure of an important trypanosomal protein ...

Here the authors analyze data from COVAIL trial participants receiving an mRNA second COVID-19 vaccine boost and show that, while neutralizing antibody titer is correlated with Omicron COVID-19 ...

A team of scientists at the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg and the University of ...

A businessman is offering $1 million prize to anyone who can prove the mRNA COVID-19 inoculations did not kill more people ...

A study published in PNAS reveals how a bacterial pathogen coordinates N-acetylneuraminic acid (Neu5Ac) metabolism at the post-transcriptional level via a novel small noncoding RNA to promote ...